加拿大皇家银行资本市场（RBC Capital Markets）近日发布研究报告，将Inspire Medical Systems的投资评级从“跑赢大盘”下调至“与板块持平”。同时，该机构将其目标股价从175美元大幅调降至90美元，降幅接近50%。
此次评级调整反映出分析师对该公司短期增长前景的谨慎态度。目标价的大幅下调可能源于对医疗器械市场竞争加剧、患者植入量增速放缓或医保政策变化的担忧。尽管Inspire Medical Systems在阻塞性睡眠呼吸暂停治疗领域具有技术优势，但当前估值水平需要更扎实的业绩支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.